Claudin-4 Expression Is Associated With Disease-Free Survival in Breast Carcinoma-in-Situ: Mean Follow-up of 8.2 Years

Furuse, 1998, Claudin-1 and -2: novel integral membrane proteins localizing at tight junctions with no sequence similarity to occludin, J Cell Biol, 141, 1539, 10.1083/jcb.141.7.1539 Gonzalez-Mariscal, 2003, Tight junction proteins, Prog Biophys Mol Biol, 81, 1, 10.1016/S0079-6107(02)00037-8 Katoh, 2003, CLDN23 gene, frequently down-regulated in intestinal-type gastric cancer, is a novel member of CLAUDIN family, Int J Mol Med, 11, 683 Hewitt, 2006, The claudin gene family: expression in normal and neoplastic tissues, BMC Cancer, 6, 186, 10.1186/1471-2407-6-186 Herschkowitz, 2007, Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors, Genome Biol, 8, R76, 10.1186/gb-2007-8-5-r76 Creighton, 2009, Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features, Proc Natl Acad Sci U S A, 106, 13820, 10.1073/pnas.0905718106 Hennessy, 2009, Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics, Cancer Res, 69, 4116, 10.1158/0008-5472.CAN-08-3441 Prat, 2010, Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer, Breast Cancer Res, 12, R68, 10.1186/bcr2635 Tokes, 2005, Claudin-1, -3 and -4 proteins and mRNA expression in benign and malignant breast lesions: a research study, Breast Cancer Res, 7, R296, 10.1186/bcr983 Kulka, 2009, Expression of tight junction protein claudin-4 in basal-like breast carcinomas, Pathol Oncol Res, 15, 59, 10.1007/s12253-008-9089-x Hammond, 2010, American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer, Arch Pathol Lab Med, 134, 907, 10.5858/134.6.907 Wolff, 2013, Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update, J Clin Oncol, 31, 3997, 10.1200/JCO.2013.50.9984 Sheehan, 2007, Loss of claudins-1 and −7 and expression of claudins-3 and −4 correlate with prognostic variables in prostatic adenocarcinomas, Hum Pathol, 38, 564, 10.1016/j.humpath.2006.11.007 Ricardo, 2012, Claudin expression in breast cancer: high or low, what to expect?, Histol Histopathol, 27, 1283 Kominsky, 2003, Loss of the tight junction protein claudin-7 correlates with histological grade in both ductal carcinoma in situ and invasive ductal carcinoma of the breast, Oncogene, 22, 2021, 10.1038/sj.onc.1206199 Lanigan, 2009, Increased claudin-4 expression is associated with poor prognosis and high tumour grade in breast cancer, Int J Cancer, 124, 2088, 10.1002/ijc.24159 Lu, 2013, Claudin expression in high grade invasive ductal carcinoma of the breast: correlation with the molecular subtype, Mod Pathol, 26, 485, 10.1038/modpathol.2012.187 Abd-Elazeem, 2015, Claudin 4 expression in triple-negative breast cancer: correlation with androgen receptors and Ki-67 expression, Ann Diagn Pathol, 19, 37, 10.1016/j.anndiagpath.2014.10.003 Aberle, 1996, Cadherin–catenin complex: protein interactions and their implications for cadherin function, J Cell Biochem, 61, 514, 10.1002/(SICI)1097-4644(19960616)61:4<514::AID-JCB4>3.0.CO;2-R Park, 2007, Expression pattern of adhesion molecules (E-cadherin, α-, β-, γ-catenin and claudin-7), their influenceon survival in primary breast carcinoma,and their corresponding axillary lymph node metastasis, APMIS, 115, 52, 10.1111/j.1600-0463.2007.apm_524.x Szasz, 2011, Identification of a claudin-4 and E-cadherin score to predict prognosis in breast cancer, Cancer Sci, 102, 2248, 10.1111/j.1349-7006.2011.02085.x Rakovitch, 2015, A population-based validation study of the DCIS score predicting recurrence risk in individuals by breast-conserving surgery alone, Breast Cancer Res Treat, 152, 389, 10.1007/s10549-015-3464-6 Francis, 2015, Addressing overtreatment of screen detected DCIS; the LORIS trial, Eur J Cancer, 51, 2296, 10.1016/j.ejca.2015.07.017